Search results for "C25"

showing 10 items of 566 documents

Propiedades psicométricas del cuestionario de afronta¬miento al estrés para pacientes oncológicos (CAEPO)

2017

Los objetivos del estudio fueron: 1) analizar la estructura factorial de la escala CAEPO mediante análisis factorial exploratorio y confirmatorio; 2) estimar la consistencia interna de los factores; 3) describir la distribución de los factores; 4) analizar las diferencias de medias de las estrategias de afrontamiento entre hombres y mujeres. El Cuestionario de Afrontamiento al Estrés para Pacientes Oncológicos (CAEPO) de González (2004) fue aplicado a 148 pacientes oncológicos. Se sugiere reducir la escala a 35 ítems. Se encontró una estructura de cuatro factores correlacionados con consistencias internas de adecuadas a altas. La distribución de los factores se ajustó a una curva normal y n…

avoidanceAfrontamiento activolcsh:BF1-990ruminaterumiaciónlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282cáncer.Active copingClinical Psychologylcsh:PsychologyOncologycancer.pasividadevitaciónpassiveness
researchProduct

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.

2020

INTRODUCTION: Pancreatic cancer (PC), even in the absence of metastatic disease, has a dismal prognosis. One-third of them are borderline resectable (BRPC) or locally advanced unresectable PC (LAUPC) at diagnosis. There are limited prospective data supporting the best approach on these tumours. Neoadjuvant chemotherapy (ChT) is being increasingly used in this setting. METHODS: This is a retrospective series of consecutive patients staged as BRPC or LAUPC after discussion in the multidisciplinary board (MDB) at an academic centre. All received neoadjuvant ChT, followed by chemoradiation (ChRT) in some cases, and those achieving enough downstaging had a curative-intent surgery. Descriptive da…

borderline resectableCancer Researchmedicine.medical_specialtyFOLFIRINOXmedicine.medical_treatmentpancreatic cancerNeutropeniaAdenocarcinomalcsh:RC254-282Pancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective Studies1506Neoadjuvant therapyRetrospective StudiesOriginal ResearchChemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslocally advanced unresectableNeoadjuvant TherapyOxaliplatinSurgeryIrinotecanPancreatic NeoplasmsFOLFIRINOXOncologyFluorouracilbusinessmedicine.drugESMO open
researchProduct

Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment

2021

Despite the recent advances in cancer patient management and in the development of targeted therapies, systemic chemotherapy is currently used as a first-line treatment for many cancer types. After an initial partial response, patients become refractory to standard therapy fostering rapid tumor progression. Compelling evidence highlights that the resistance to chemotherapeutic regimens is a peculiarity of a subpopulation of cancer cells within tumor mass, known as cancer stem cells (CSCs). This cellular compartment is endowed with tumor-initiating and metastasis formation capabilities. CSC chemoresistance is sustained by a plethora of grow factors and cytokines released by neighboring tumor…

cancer stem cells0301 basic medicineCancer ResearchDNA repairmedicine.medical_treatmentReviewTargeted therapy03 medical and health sciences0302 clinical medicineImmune systemCancer stem celltumor microenvironmentMedicinecancer stem cells tumor microenvironment anticancer drugs chemoresistance targeted therapyRC254-282Tumor microenvironmentbusiness.industrychemoresistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancertargeted therapymedicine.diseaseanticancer drugs030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisCancer cellCancer researchSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratoriobusiness
researchProduct

Metabolic Escape Routes of Cancer Stem Cells and Therapeutic Opportunities

2020

Although improvement in early diagnosis and treatment ameliorated life expectancy of cancer patients, metastatic disease still lacks effective therapeutic approaches. Resistance to anticancer therapies stems from the refractoriness of a subpopulation of cancer cells—termed cancer stem cells (CSCs)—which is endowed with tumor initiation and metastasis formation potential. CSCs are heterogeneous and diverge by phenotypic, functional and metabolic perspectives. Intrinsic as well as extrinsic stimuli dictated by the tumor microenvironment (TME)have critical roles in determining cell metabolic reprogramming from glycolytic toward an oxidative phenotype and vice versa, allowing cancer cells to th…

cancer stem cells0301 basic medicinecancer stem cellCancer ResearchStromal cellSettore MED/50 - Scienze Tecniche Mediche ApplicateCellcancer metabolismReviewTumor initiationlcsh:RC254-282glycolysi03 medical and health sciences0302 clinical medicineCancer stem celllipid metabolismmicroRNAtumor microenvironmentmetabolic reprogrammingMedicinemetabolism-based anticancer drugsTumor microenvironmentbusiness.industryglycolysislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOXPHOSMicrovesicles030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer cellCancer researchSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratoriobusinessCancers
researchProduct

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness

2021

Simple Summary Breast cancer (BC) is not a single disease, but a group of different tumors, and altered HER2 expression defines a particularly aggressive subtype. Although HER2 pharmacological inhibition has dramatically improved the prognosis of HER2-positive BC patients, there is still an urgent need for improved knowledge of HER2 biology and mechanisms underlying HER2-driven aggressiveness and drug susceptibility. Emerging data suggest that the clinical efficacy of molecularly targeted therapies is related to their ability to target breast cancer stem cells (BCSCs), a population that is not only self-sustaining and able to differentiate into distinct lineages, but also contributes to tum…

cancer stem cellsCancer ResearchBreast cancer Cancer stem cells D16HER2 splice variant Drug resistance Full-length HER2 P95HER2Stemness signaling pathwaysmedicine.medical_treatmentContext (language use)ReviewBiologymedicine.disease_caused16HER2 splice variantMetastasisTargeted therapyfull-length HER2Breast cancerbreast cancerCancer stem cellmedicineskin and connective tissue diseasesp95HER2RC254-282drug resistancestemness signaling pathwaysNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncologyCancer researchStem cellSignal transductionCarcinogenesisCancers
researchProduct

Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells

2022

Despite advances in the curative approach, the survival rate of advanced colorectal cancer (CRC) patients is still poor, which is likely due to the emergence of cancer cell clones resistant to the available therapeutic options. We have already shown that CD44v6-positive CRC stem cells (CR-CSCs) are refractory toward standard anti-tumor therapeutic agents due to the activation of the PI3K pathway together with high HER2 expression levels. Tumor microenvironmental cytokines confer resistance to CR-CSCs against HER2/PI3K targeting by enhancing activation of the MAPK pathway. Here, we show that the CSC compartment, spared by BRAF inhibitor-based targeted therapy, is associated with increased ex…

cancer stem cellsCancer ResearchOncologySettore MED/04 - PATOLOGIA GENERALECancer stem cellCombination therapies.anti-tumor drug resistanceanti-tumor drug resistance; colorectal cancer; combination therapies; cancer stem cellsNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal cancerSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratoriocombination therapiesRC254-282Cancers
researchProduct

Colorectal Cancer Stem Cells and Cell Death

2011

Nowadays it is reported that, similarly to other solid tumors, colorectal cancer is sustained by a rare subset of cancer stem-like cells (CSCs), which survive conventional anticancer treatments, hanks to efficient mechanisms allowing escape from apoptosis, triggering tumor recurrence. To improve patient outcomes, conventional anticancer therapies have to be replaced with specific approaches targeting CSCs. In this review we provide strong support that BMP4 is an innovative therapeutic approach to prevent colon cancer growth increasing differentiation markers expression and apoptosis. Recent data suggest that in colorectal CSCs, protection from apoptosis is achieved by interleukin-4 (IL-4) a…

cancer stem cellsCancer ResearchProgrammed cell deathColorectal cancerSurvivingBMP4Reviewsurvivinlcsh:RC254-282Cancer stem cellSurvivinmedicineAutocrine signallingbusiness.industryCancer stem cellapoptosisCancerApoptosilcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncologyApoptosisImmunologyCancer researchStem cellbusinessCancers
researchProduct

Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment

2014

Cancer is one of the most urgent health issues of today. According to WHO, the number of cancer cases is expected to increase by 75% in the next two decades (1). Despite some remarkable achievements in the fields of cancer prevention and early detection, the goal of developing effective anti-cancer therapies still remains unmet. Tumor recurrence due to treatment resistance is the most common cause of death from cancer. Delineating cellular and molecular mechanisms underlying tumor recurrence is of prime importance for the ability to improve the efficacy of existing therapies and develop new strategies to cancer treatment.

cancer stem cellsCancer Researchmedicine.medical_specialtytumor clones selectionEarly detectionintratumor heterogeneityBioinformaticslcsh:RC254-282Intratumor heterogeneityCancer stem cellmedicinecancerTreatment resistanceIntensive care medicineCancer preventionbusiness.industryintratumor spatiotemporal patternsCancerOpinion Articlelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetumor recurrenceCancer treatmentTumor recurrenceOncologybusinessanti-cancer therapyFrontiers in Oncology
researchProduct

Dissecting the Mechanism of Action of Spiperone—A Candidate for Drug Repurposing for Colorectal Cancer

2022

Approximately 50% of colorectal cancer (CRC) patients still die from recurrence and metastatic disease, highlighting the need for novel therapeutic strategies. Drug repurposing is attracting increasing attention because, compared to traditional de novo drug discovery processes, it may reduce drug development periods and costs. Epidemiological and preclinical evidence support the antitumor activity of antipsychotic drugs. Herein, we dissect the mechanism of action of the typical antipsychotic spiperone in CRC. Spiperone can reduce the clonogenic potential of stem-like CRC cells (CRC-SCs) and induce cell cycle arrest and apoptosis, in both differentiated and CRC-SCs, at clinically relevant co…

cancer stem cellsCancer ResearchrepurposingNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal cancerpsychotropic drugsrepurposing; phospholipase C; colorectal cancer; endoplasmic reticulum stress; intracellular calcium; lipid metabolism; psychotropic drugs; cancer stem cells; mitochondria; GolgimitochondriaOncologylipid metabolism&nbspGolgiendoplasmic reticulum stressSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratoriophospholipase CRC254-282intracellular calciumCancers
researchProduct

Radioactive Beams for Image-Guided Particle Therapy: The BARB Experiment at GSI

2021

Several techniques are under development for image-guidance in particle therapy. Positron (β+) emission tomography (PET) is in use since many years, because accelerated ions generate positron-emitting isotopes by nuclear fragmentation in the human body. In heavy ion therapy, a major part of the PET signals is produced by β+-emitters generated via projectile fragmentation. A much higher intensity for the PET signal can be obtained using β+-radioactive beams directly for treatment. This idea has always been hampered by the low intensity of the secondary beams, produced by fragmentation of the primary, stable beams. With the intensity upgrade of the SIS-18 synchrotron and the isotopic separati…

carbon ionsPETparticle therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensradioactive ion beamsRC254-282oxygen ionsFrontiers in Oncology
researchProduct